Association of long-term adherence to evidence-based combination drug therapy after acute myocardial infarction with all-cause mortality. A prospective cohort study based on claims data

European Journal of Clinical Pharmacology

Volumn 68, Issue 10, 2012, Pages 1451-1460

  Kuepper Nybelen, Jutta ^a   Hellmich, Martin ^b   Abbas, Sascha ^a   Ihle, Peter ^a   Griebenow, Reinhard ^a   Schubert, Ingrid ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Claims data; Drug therapy combination; Guideline; Medication adherence; Mortality; Myocardial infarction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL PRACTICE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEALTH INSURANCE; HEART PROTECTION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY PREVENTION;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GERMANY; GUIDELINE ADHERENCE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MEDICATION ADHERENCE; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES;

EID: 84866621034     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1274-x     Document Type: Article

References (38)

1. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K, together with members of the Task Force (1998) Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. J Hypertens 16:1407-1414
2. Deutsche Gesellschaft für Kardiologie-, Herz- und Kreislaufforschung (1998) Leitlinie koronare Herzkrankheit/Angina pectoris. Z Kardiol 87:907-911
3. Dietz R, Rauch B (2003) Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie-Herz- und Kreislaufforschung (DGK). Z Kardiol 92:501-521
4. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP et al (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106:388-391
5. Mehta RH, Montoye CK, Gallogly M, Baker P, Blount A, Faul J et al (2002) Improving quality of care for acute myocardial infarction -the guidelines applied in practice (GAP) initiative. JAMA 287:1269-1276
6. Liem SS, van der Hoeven BL, Oemrawsingh PV, Bax JJ, van der Bom JG, Bosch J et al (2007) MISSION! Optimization of acute and chronic care for patients with acute myocardial infarction. Am Heart J 153:14.e1-14.e11
7. Woods KL, Ketley D, Lowy A, Agusti A, Hagn C, Kala R et al (1998) Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction. Towards an understanding of factors influencing clinical practice. Eur Heart J 19:74-79
8. Velasco JA (1999) After 4S, CARE and LIPID-Is evidence-based medicine being practised? Atherosclerosis 147(Suppl 1):S39-44
9. Brady AJ, Oliver MA, Pittard JB (2001) Secondary prevention in 24431 patients with coronary heart disease: survey in primary care. BMJ 322:1463
10. Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462-467
11. Heidrich J, Liese AD, Kalic M, Winter-Enbergs A, Wellmann J, Roeder N et al (2002) Sekundärprävention der koronaren Herzkrankheit. Ergebnisse der EuroASPIRE I- und II-Studien in der Region Münster. Dtsch Med Wochenschr 127:667-672
12. Böger GI, Hoopmann M, Busse R, Budinger M, Welte T, Böger RH (2003) Arzneimittelverordnungen bei koronarer Herzkrankheit: Werden die Therapieempfehlungen beachtet?. Z Kardiol 92:466-475
13. Küpper-Nybelen J, Rothenbacher D, Hahmann H, Wüsten B, Brenner H (2003) Veränderungen von Risikofaktoren nach stationärer Rehabilitation bei Patienten mit koronarer Herzkrankheit. Dtsch Med Wochenschr 128:1525-1530
14. Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD et al (2004) Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 117:73-81
15. Austin PC, Tu JV, Ko DT, Alter DA (2008) Use of evidence-based therapies after discharge among elderly patients with acute myocardial infarction. CMAJ 179:895-900
16. Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL (2009) Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 122:961.e7-961.e12
17. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA (2004) Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 109:745-749
18. Rogers AM, Ramanath VS, Grzybowski M, Riba AL, Jani SM, Mehta R et al (2007) The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) initiative in Michigan. Am Heart J 154:461-469
19. Gouya G, Reichardt B, Ohrenberger G, Wolzt M (2007) Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. Eur J Epidemiol 22:145-149
20. Jackevicius CA, Li P, Tu JV (2008) Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 117:1028-1036
21. Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, Ransohoff DF, Sindelar J (1990) Treatment adherence and risk of death after a myocardial infarction. Lancet 336:542-545
22. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS (2006) Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 166:1842-1847
23. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS (2006) Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 6:48
24. Newby LK, Allen LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM (2006) Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113:203-212
25. Rasmussen JN, Chong A, Alter AD (2007) Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297:177-186
26. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS (2008) Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 155:772-779
27. Vokó Z, de Brouwer S, Lubsen J, Danchin N, Otterstad J-E, Dunselman PHJM, Kirwan B-A (2011) Long-term impact of secondary preventive treatments in patients with stable angina. Eur J Epidemiol. doi:10.1007/s10654- 011-9558-5
28. Ihle P, Köster I, Herholz H, Rambow-Bertram P, Schardt T, Schubert I (2005) Versichertenstichprobe AOK Hessen/KV Hessen - Konzeption und Umsetzung einer personenbezogenen Datenbasis aus der gesetzlichen Krankenversicherung. Gesundheitswesen 67:638-645
29. Johnson ES, Mozaffari E (2002) Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am J Manag Care 8:S249-254
30. Daly CA, De Stavola B, Sendon JLL, Tavazzi L, Boersma E, Clemens F et al (2006) Predicting prognosis in stable angina- results from the Euro Heart Survey of stable angina: prospective observational study. BMJ 332:262-267
31. Donner-Banzhoff N, Held K, Laufs U, Trappe H-J, Werdan K, Zerkowski H-R (2010) Nationale VersorgungsLeitlinie Chronische KHK. Langfassung. 2010; version 1.9, based on version from June 2006 http://www.versorgungsleitlinien.de/ themen/khk/pdf/ nvl-khk-lang.pdf. Accessed 5 Nov 2010
32. Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16:241-249
33. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55
34. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S (2006) A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 59:437-447
35. Briffa T, Hickling S, Knuiman M, Hobbs M, Hung J, Sanfilippo FM, Jamrozik P, Thompson PL (2009) Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984-2005. BMJ 338:b36
36. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC (2008) Improvement in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge. A 10-year trend analysis. J Am Coll Cardiol 51:1247-1254
37. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333:15
38. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH (2007) Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 166:348-354